126 related articles for article (PubMed ID: 20449837)
1. Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2.
Kaiser A; Gaidzik N; Becker T; Menge C; Groh K; Cai H; Li YM; Gerlitzki B; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2010 May; 49(21):3688-92. PubMed ID: 20449837
[No Abstract] [Full Text] [Related]
2. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of MUC1-lipopeptide chimeras.
Wilkinson BL; Malins LR; Chun CK; Payne RJ
Chem Commun (Camb); 2010 Sep; 46(34):6249-51. PubMed ID: 20664875
[TBL] [Abstract][Full Text] [Related]
4. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
5. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin.
Dziadek S; Kowalczyk D; Kunz H
Angew Chem Int Ed Engl; 2005 Nov; 44(46):7624-30. PubMed ID: 16247814
[No Abstract] [Full Text] [Related]
6. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
Dziadek S; Hobel A; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
[No Abstract] [Full Text] [Related]
7. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.
Hoffmann-Röder A; Kaiser A; Wagner S; Gaidzik N; Kowalczyk D; Westerlind U; Gerlitzki B; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2010 Nov; 49(45):8498-503. PubMed ID: 20878823
[No Abstract] [Full Text] [Related]
8. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer.
Kang JY; Nan X; Jin MS; Youn SJ; Ryu YH; Mah S; Han SH; Lee H; Paik SG; Lee JO
Immunity; 2009 Dec; 31(6):873-84. PubMed ID: 19931471
[TBL] [Abstract][Full Text] [Related]
9. Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.
Thompson P; Lakshminarayanan V; Supekar NT; Bradley JM; Cohen PA; Wolfert MA; Gendler SJ; Boons GJ
Chem Commun (Camb); 2015 Jun; 51(50):10214-7. PubMed ID: 26022217
[TBL] [Abstract][Full Text] [Related]
10. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
[TBL] [Abstract][Full Text] [Related]
11. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response.
Westerlind U; Hobel A; Gaidzik N; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2008; 47(39):7551-6. PubMed ID: 18704911
[No Abstract] [Full Text] [Related]
12. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
Gaidzik N; Westerlind U; Kunz H
Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
[TBL] [Abstract][Full Text] [Related]
13. Synthetic glycopeptides for the development of cancer vaccines.
Liakatos A; Kunz H
Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
[TBL] [Abstract][Full Text] [Related]
14. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand.
Abdel-Aal AB; El-Naggar D; Zaman M; Batzloff M; Toth I
J Med Chem; 2012 Aug; 55(15):6968-74. PubMed ID: 22800462
[TBL] [Abstract][Full Text] [Related]
15. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.
Wilkinson BL; Day S; Malins LR; Apostolopoulos V; Payne RJ
Angew Chem Int Ed Engl; 2011 Feb; 50(7):1635-9. PubMed ID: 21308921
[No Abstract] [Full Text] [Related]
16. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
[TBL] [Abstract][Full Text] [Related]
17. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.
Kaiser A; Gaidzik N; Westerlind U; Kowalczyk D; Hobel A; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2009; 48(41):7551-5. PubMed ID: 19685547
[No Abstract] [Full Text] [Related]
18. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.
Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389
[TBL] [Abstract][Full Text] [Related]
19. Two modes of ligand recognition by TLRs.
Brodsky I; Medzhitov R
Cell; 2007 Sep; 130(6):979-81. PubMed ID: 17889640
[TBL] [Abstract][Full Text] [Related]
20. Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response.
Cai H; Huang ZH; Shi L; Sun ZY; Zhao YF; Kunz H; Li YM
Angew Chem Int Ed Engl; 2012 Feb; 51(7):1719-23. PubMed ID: 22247051
[No Abstract] [Full Text] [Related]
[Next] [New Search]
